CBD Processing Is Back on the Menu for North

What North’s CBD Move Means for Your Fees, Risk, and Options

When a big processor reopens CBD, it usually means two things at once: more access and more risk pricing baked into your statement. North’s decision to officially reopen its CBD vertical on April 1, 2026 is no exception. For ingestible CBD merchants, the way you approach this move will determine whether you simply get approved or get approved on terms that actually make sense for your business.

A quick rewind. Cannabis, CBD, and card acceptance

Over the past year, the cannabis conversation has shifted from “if” to “how fast.” Regulatory momentum around federal cannabis rescheduling has started to open doors for banking, card acceptance, and more “normal” financial services, but it has not turned cannabis into a low risk category overnight. In our recent VeriFee article on cannabis reclassification, we walked through how even a positive policy shift still leaves operators navigating heightened underwriting, higher effective rates, and real uncertainty about how quickly card brands and banks will adapt.

CBD sits in the middle of that story. Hemp derived CBD with less than 0.3 percent THC has been federally legal since the 2018 Farm Bill, but that legal status has never translated into friction-free card acceptance. Banks and processors continue to classify CBD, especially ingestible products, as high risk because of evolving federal guidance, inconsistent state level rules, and the ever present fear that an enforcement change can land on their desk with zero warning.

That is the backdrop for North’s move to reopen CBD. The access matters. The risk pricing does too.

What North is changing on April 1

According to North’s internal communication, the company is officially reopening the CBD vertical beginning April 1, 2026 and will once again board both card present and card not present merchants whose sales of ingestible CBD and derivative products account for more than 15 percent of total sales. That threshold is important because it signals that North is consciously stepping back into true CBD merchants, not just edge case retailers with a few topical products.

On its CBD industry page, North is explicit that it wants to be seen as CBD-friendly. The company notes that CBD businesses have traditionally been considered specialty or hard-to-place businesses and that at present merchants selling CBD need specialty merchant accounts to accept credit and debit cards. It positions its CBD program as a way for merchants to access those specialty accounts and the hardware and software around them in a more streamlined way.

North also emphasizes that, unlike some financial institutions, it does not discriminate against CBD merchants or the potential risks of the CBD industry. In practice, that stance shows up in a product mix that includes:

In-store acceptance: EMV and contactless terminals, Payanywhere smart devices, and point of sale systems tailored to retail environments
Online and remote acceptance: ecommerce integrations and virtual terminals that support card-not-present CBD transactions
Risk tools: chargeback reporting and fraud controls designed for categories that see more scrutiny

For CBD merchants who have been stuck in a pattern of “no” or “call us back when your product mix changes,” this reopening is a genuine opportunity to secure or expand card acceptance on a stable platform. But it is not a blank check.

Why CBD is still treated as high risk

The reality is that CBD never graduated out of the high-risk bucket. It simply gained slightly better company. Even after hemp-derived CBD became legal at the federal level, many acquirers and sponsor banks continued to view the category as high risk and, in some cases, reputationally sensitive.

Industry analyses of CBD processing are remarkably consistent on a few points:

CBD is still classified as high risk because of evolving regulations, inconsistent state-level legislation, and ongoing scrutiny from financial institutions
Even compliant CBD brands face higher fees and more stringent scrutiny than their mainstream retail counterparts
Underwriting teams worry not just about what you are selling today, but what you might sell tomorrow and how quickly regulators or card brands could change their stance

That last point is critical. When a vertical lives under the shadow of regulatory changes that can happen on a dime, risk and compliance teams price in that optionality. They know that if the FDA tightens guidance on ingestible CBD or if card brands update their rules, they may have to quickly reunderwrite portfolios, adjust risk thresholds, or even offboard certain merchants.

From a merchant’s perspective, that uncertainty shows up as:

Elevated discount rates compared with standard retail
Higher per transaction fees, particularly on card-not-present and keyed transactions
Rolling reserves that hold back a percentage of your revenue for months at a time
Tighter volume caps and more frequent reviews of your product catalog and marketing

These dynamics are very similar to what we see in THC and broader cannabis processing, where many merchants end up paying multiples of what a typical retail operation would pay to move the same dollar volume.

Card present vs card not present: why both channels matter

One of the most notable parts of North’s reopening is that it explicitly includes both card present and card not present CBD merchants above the 15 percent ingestible threshold. That sounds like a small detail, but in payment terms, it is a significant shift.

A card-present transaction is one where the card and the customer are physically present, and the card is dipped, tapped, or swiped at a terminal. Processors and card networks generally view these transactions as lower risk because the card is authenticated in person and there is typically more evidence if a dispute arises. Card present CBD sales at a retail counter fall into this bucket.

Card not present transactions are a different animal. A card not present payment occurs when neither the cardholder nor the credit card is physically present at the time of the transaction. That includes ecommerce orders, phone sales, and subscriptions. Most online CBD brands, subscription wellness companies, and telehealth plus CBD models live squarely in this card not present world.

Card not present transactions carry:

Higher fraud risk because the card details can be stolen or misused more easily
Higher chargeback risk, especially for products like ingestible CBD that some customers still view skeptically
Higher interchange and processor markups in many pricing structures, simply because they are statistically riskier

When you combine ingestible CBD with card not present sales, you are stacking multiple risk layers that both banks and processors care about. That is one reason articles on CBD payment gateways warn merchants to expect stricter underwriting, more monitoring, and higher fees for online CBD stores than for straightforward in-store sales.

North’s willingness to board both channels is positive because it recognizes how modern CBD businesses actually sell. Merchants should assume that their risk profile will be evaluated differently for ecommerce compared with in store sales and that pricing and reserves may reflect those differences.

Where the higher fees and reserves come from

CBD merchants often end up paying significantly more than their neighbors, even with a friendly processor. A few structural reasons show up repeatedly in high-risk verticals such as CBD:

Category based risk premiums. High-risk labels allow providers to charge higher base rates and per transaction markups than they would in mainstream categories, even when the actual fraud and chargeback performance of a particular merchant is relatively clean.
Rolling reserves and slower funding. Many high-risk CBD processors require merchants to keep a portion of their transaction proceeds in a rolling reserve account, often 5 to 10 percent held for 90 to 180 days as a buffer against chargebacks. That is on top of longer standard settlement times, for example 24 to 72 hours rather than near-realtime funding.
Risk-adjusted contract terms. It is common to see multi year contracts, early termination fees, and volume caps baked into high-risk CBD agreements. Those constraints are justified internally as ways to manage portfolio risk and protect the acquirer’s investment in underwriting and onboarding.
Regulatory uncertainty baked into pricing. When regulators and card brands can change expectations quickly, whether on labeling, health claims, or product formulations, acquirers may preemptively price accounts higher to offset the risk that part of their CBD book becomes non-compliant or loss making.

North’s CBD content acknowledges this reality by emphasizing that CBD merchants need specialty merchant accounts and may be subject to additional conditions such as reserves. Similar guidance from other high-risk processors notes that CBD merchants should expect higher fees, reserve requirements, and stricter underwriting compared to standard retail.

In your cannabis reclassification article, we called out the same pattern on the THC side. Even as policy shifts open more doors, the earliest and often loudest doors are the ones charging premium pricing for that access. CBD continues to live in that world.

What North’s reopening really means for CBD merchants

Stepping back, North’s April 1 change is good news with clear conditions attached. For ingestible CBD and derivative products it:

Expands the pool of acquirers willing to underwrite you above a 15 percent CBD revenue mix
Gives you the option to consolidate in-store and online acceptance under one provider with integrated hardware and reporting
Signals that at least one major processor believes it can price and manage CBD risk profitably again, which is a vote of confidence in the category’s stability

These positives do not erase the structural realities outlined above. CBD remains a high-risk label in the eyes of banks and card networks, particularly for ingestible products sold online. You should expect:

Higher effective rates than typical retail unless you actively benchmark and negotiate
Greater likelihood of reserves or delayed funding, particularly if you are heavily card not present or scaling quickly
Ongoing compliance and product reviews, including scrutiny of your website claims, labeling, and marketing

Most importantly, the risk factors that justified this pricing yesterday will be reevaluated tomorrow. A single policy update or enforcement wave can cause processors to tighten reserves, reprice parts of their book, or change their appetite for certain subverticals. If you are not watching your statements and terms closely, those adjustments show up as quiet cost increases over time.

How VeriFee helps you use options like North without overpaying

At VeriFee, we exist because of this dynamic. The businesses that most need card acceptance are often the ones most likely to be overcharged, over reserved, or quietly repriced as the rules change. We see it in cannabis, in CBD, and across other high-risk categories that do not fit standard underwriting templates.

When a processor such as North reopens CBD, our stance is straightforward:

We are glad merchants have more options
We want you to walk into those options with clear visibility into cost, terms, and what high risk actually means on paper

Concretely, that looks like:

Statement and proposal analysis. We break down CBD pricing proposals and live statements into clear, apples-to-apples views of your effective rate by channel, card type, and fee category. That includes spotting hidden surcharges, inflated card not present markups, and miscellaneous risk or compliance add ons that quietly raise your cost per transaction.
Benchmarking against your risk profile. We compare your quoted or current CBD terms to what we see across similar merchants with comparable volume, CBD share, and ecommerce versus in store mix. The question we ask is simple. Are you being priced like your risk or like the worst case scenario in the portfolio.
Negotiation support where possible. In many cases, there is room to adjust certain levers, such as reserve structures, contract length, or the way specific fee categories are applied, especially when a merchant can demonstrate clean chargeback performance and strong compliance practices. We help you package that story and push for terms that reflect your actual behavior, not just your category label.
Ongoing monitoring as rules shift. Because CBD and cannabis policy can change quickly, we treat this as an ongoing relationship, not a one time audit. When regulators, card brands, or processors adjust their stance, we want our customers to see those changes on their statements in real time, not six months after margins have silently eroded.

Our earlier cannabis reclassification piece made a key point that applies here. Regulatory progress is real, but it does not automatically translate into fair pricing for merchants. The same is true for CBD processing. North’s reopening is a step forward on access. Whether it becomes a step forward on affordability depends on how proactively CBD merchants interrogate the fine print.

What you should do next if you sell CBD

If ingestible CBD or derivative products make up a meaningful part of your revenue, especially if it is above that 15 percent threshold, North’s April 1 change should be on your radar. Here are practical steps to take:

Inventory your current setup. Document your existing processor or processors, your CBD share of total sales, your card present versus card not present mix, and your effective rate including all fees.
Request clear proposals. If you are considering North or any other CBD friendly processor, insist on transparent, line item quotes that separate base rates, card not present markups, and any risk or compliance fees.
Scrutinize reserves and terms. Look beyond headline rates to reserve requirements, contract length, termination clauses, and funding timelines. High-risk categories hide a lot of cost in these details.
Have an expert review the numbers. Before you sign or before you assume your current deal is as good as it gets, have a third party who lives in this space break down the math and the risk logic with you.

That is the role VeriFee was built to play. If you are weighing a move to North’s reopened CBD program or trying to understand whether your existing CBD processing setup reflects your real risk or just your category label, we can help you separate access from excess.